Belgian pharmaceutical company UCB SA has agreed to buy Zogenix Inc., a U.S. maker of drugs to treat seizures and rare diseases, for as much as $1.9 billion, expanding its portfolio to treat epilepsy.
To read the entire story, you must be logged in.
Please log in now or register with us.
